Monopar Therapeutics

MNPR

Market cap $521M

Upgrade to unlock

Buy

Hold

Sell

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

Avg. target

$110

41% upside

High target

9 analyst ratings

positive

0 neutral

0%

negative

Analyst & Firm	Rating	Price Target	Upside Downside	Date
Raymond James Chris Raymond 50% 1-yr MNPR win rate				14 Nov ‘25 20 days ago
Chardan Capital Keay Nakae 83% 1-yr MNPR win rate				13 Nov ‘25 21 days ago
Leerink Partners Joseph Schwartz 0% 1-yr MNPR win rate				10 Nov ‘25 24 days ago
Barclays Etzer Darout 0% 1-yr MNPR win rate				13 Oct ‘25 1 month ago
Oppenheimer Andreas Argyrides 50% 1-yr MNPR win rate				2 Oct ‘25 2 months ago
HC Wainwright & Co Andres Maldonado 100% 1-yr MNPR win rate				29 Sep ‘25 2 months ago
Piper Sandler Biren Amin 100% 1-yr MNPR win rate				25 Sep ‘25 2 months ago
BTIG Jeet Mukherjee 100% 1-yr MNPR win rate				25 Sep ‘25 2 months ago
Lake Street Chad Messer 100% 1-yr MNPR win rate				23 Sep ‘25 2 months ago